You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Bio-Rad's year-over-year Q3 revenue increase was driven primary by sales of PCR and Droplet Digital PCR products due to the COVID-19 pandemic.
Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.
The "EV Click Chip" process involves collecting and purifying extracellular vesicles from a blood sample before performing RT-ddPCR to identify up to 10 early-stage HCC biomarkers.
The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.
In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.
The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
Droplet digital PCR tests for SARS-CoV-2 can potentially detect the very low viral loads seen in asymptomatic and convalescent cases.
The technology uses single-cell droplet digital PCR to analyze maternal blood cell populations that have been enriched for fetal cells by MACS.
Having raised $1.5 million in funding since announcing the project at a 2017 AACR meeting, the group anticipates completing the first phase of the project by Q2 2020.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.